中药大品种二次开发研究是中药创新研究的重要内容,是继承和发展中医药理论、突破制约中医药理论和中药产业发展瓶颈的重要路径。药效物质基础和作用机制研究是中药大品种二次开发的核心内容。对丹红化瘀口服液的药效物质基础和作用机制进行了系统总结,即通过对原料药材、复方制剂以及口服后血中移行成分的系统辨识,阐释丹红化瘀口服液的主要化学物质组和潜在有效成分;进一步通过网络药理学预测分析和相关受体活性测试实验,筛选和明确了其主要药效物质基础;通过与视网膜中央静脉阻塞症相关的整体动物模型、网络药理学分析、相关功能受体结合及酶学检测研究,阐释了丹红化瘀口服液的作用机制,为该药的临床应用和质量控制提供科学依据。

To study the secondary development of major Chinese materia medica (CMM) varieties is the important content of CMM innovation research, and it is also the important approach of inheriting and developing traditional Chinese medicine (TCM) theory and breaking the bottleneck restricting the development of TCM theory and CMM industry development. The study of pharmacodynamic material basis and mechanism is the core content of the secondary development of CMM. The study on the material basis and mechanism of Danhong Huayu Oral Liquid (丹红化瘀口服液) was reviewed in this paper. The chemical components of Danhong Huayu Oral Liquid were elucidated by identification and characterization of herbs, Danhong Huayu Oral Liquid and components ingested into the blood. Through the network pharmacology prediction analysis and related receptor activity test experiment, the main pharmacodynamic material basis was screened and identified. The mechanism of Danhong Huayu Oral Liquid was explained by the studies of animal models, network pharmacology, and functional receptors related with central retinal vein occlusion, in order to provide a scientific basis for the clinical application and quality control of Danhong Huayu Oral Liquid.

R285.5

国家自然科学基金重点项目（81830111）；中央引导地方科技发展专项资助项目（20ZYCGSN00200）